{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"DCR was defined as the percentage of participants who achieved a best overall response (BOR) of confirmed CR, confirmed PR, or SD out of all participants treatment. Best response is determined from a sequence of responses assessed. Two determinations of PR or better before progression, but not qualifying for a CR, are required for a best response of PR. CR is defined as the disappearance of all targeted and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions.","groups":[{"description":"Participants received high dose LY3499446 as oral monotherapy BID in 21-day cycles.","id":"OG000","title":"LY3499446 Phase 1 Cohort A1 (High Dose)"},{"description":"Participant received mid dose LY3499446 as oral monotherapy once QOD in 21-day cycles.","id":"OG001","title":"LY3499446 Phase 1 Cohort AO (Mid Dose)"},{"description":"Participants received low dose LY3499446 as oral monotherapy once QD in 21-day cycles.","id":"OG002","title":"LY3499446 Phase 1 Cohort A-2 (Low Dose)"}],"populationDescription":"Zero participants were analyzed due to early termination of study.","reportingStatus":"POSTED","timeFrame":"Baseline through Measured Progressive Disease (Up to 11 Months)","title":"Phase 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and SD","type":"SECONDARY"}